Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13712545 | 0.87 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3KCNH2P2RX7 | |
| SCHEMBL4635761 | 0.81 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3KCNH2P2RX7 | |
| SCHEMBL5887638 | 0.81 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| SCHEMBL4518497 | 0.80 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL5888071 | 0.80 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3KCNH2P2RX7 | |
| SCHEMBL4522716 | 0.79 | SLC6A4 (0.82) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| Hydrochloric Acid SCHEMBL4503254 | 0.78 | SLC6A4 (0.80) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 | |
| SCHEMBL5888157 | 0.77 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3KCNH2P2RX7 | |
| SCHEMBL5328738 | 0.76 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2P2RX7 | |
| SCHEMBL5887977 | 0.75 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3KCNH2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239929-A1 | N-Pyrrolidin-3-YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1828119-A1 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS | Pfizer Limited (GB) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006064332-A1 | N-PYRROLIDIN-3YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALIN RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239929-A1 | N-Pyrrolidin-3-YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | TPH1, TPH2, HTR1A | SLC6A2 7/4885SLC6A4 13/4885SLC6A3 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.